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Treatment
i) Establish a successful physician patient relationship
It is of utmost importance to establish a successful physician patient relationship and help the patient to
understand the benign nature of the illness. Physician should acknowledge the reality of patient’s
symptoms and have empathetic behaviour66. Any concerns of the patient should be discussed. Some
patients may be having fears of underlying cancer. Reassurance helps the patient cope with his
symptoms. Emphasis should be on negative findings of the screening investigations.
The complex underlying pathophysiological and psychophysiological disturbances exist in patients
with irritable bowel syndrome, treating them may be a difficult task. It has been shown that doctors
underestimate patients expectations, anxiety and secondary complaints and overestimate patients’ pain
related attributions 67. Any exacerbating factors should be identified and appropriate changes made in
the dietary habits and life style. Education of patient and reassurance is importanr68.
ii) Look after Psychological Aspects
If the symptoms are clearly related to stresses and psychological strain, these patients may require
anxioly’tics and antidepressants e.g tricyclic antidepressants or Serotonin reuptake inhibitors.
Sometimes need may arise to refer one of these patients to a psychiatrist. Before referring, the patient
should be taken into confidence about the need of second opinion, with assurance of continuous
medical care. Psychological treatment offered to the patient may include psychotherapy69,
hypnotherapy70 and biofeedback71. Patients with overt psychiatric symptoms and those with diarrhea
and intermittent pain exacerbated by stress, show a good response to psychotherapy72. In an analysis of
controlled studies on psychological treatment, eight studies showed that psychological treatment was
superior to the controlled therapy while five failed to detect a significant effect 73.
iii) Dietary Changes
Dietary changes are often effective in alleviating symptoms. Patients who have gaseous symptoms and
bloating or diarrhea may be helped by avoiding smoking and caffeine, carbonated drinks, lactose
containing foods, sweets and jams containing sorbitol or fructose. They should also avoid gas forming
beans, cabbage, lentil and legumes which are fermented in the colon by the bacteria, ending up in
gases.
iv) Fiber Supplements
Fiber supplements may help relieve constipation74,75. Fiber should be introduced gradually to avoid
excessive bloating. Bran, psyllium, ispaghula husk and methylcellulose have the ability to retain watcr
thereby increasing stool weight, preventing hard stools and accelerating intestinal transit. Any benefit
from Fiber supplementation may be a placebo effect 74-76 but it seems reasonable to utilize this effect
and give a trial of fibers to patients with lBS. The agents should be taken within an hour of the meal to
allow blending with the fecal matter. A laxative may be given to the patients in constipation phase prior
to bulking with Fiber supplements to avoid bloating and satiety and liquid should be consumed in
excess alongwith dietary fiber.
v)Medical Treatment
A number of drugs are used in the treatment of lBS. Not a single drug is effective in all the patients75.
Individual patients may benefit from one of the drugs mentioned in the table 2.

These drugs include tricyclic antidepressants, antidiarrheal agents, smooth muscle relaxants, prokinetic
drugs, somatostatin agonists, 5HT4 antagonists, Kappa opioid agonists, etc.
Low dose antidepressants are effective in improving global symptoms especially pain, a CNS mediated
effect77,78. Anticholinergic effect of these medications may also be a contributing factor in relieving
abdominal pain. Antidepressants can also modulate intestinal motor function and may have therapeutic
effect in IBS, unrelated to mood improvement 79. Patient should be reassured that these drugs are not
being prescribed for any psychiatric illness but for the other useful effects.
Smooth muscle relaxants are effective in improving global symptoms and abdominal pain80 but not
constipation or abdominal distention. Mebeverine is a specific myorelaxant for colon and does not have
the side effects of anticholinergic drugs81. Zamifenacin is a new potent gut M3 selective muscarinic
antagonist. It reduces colonic motility in lBS82. Loperamide has a relaxing effect on localized and
segmental large bowel spasms. A double blind placebo controlled trial has shown its benefit with
regards to stool frequency, stool consistency and the overall pain intensity83. Morning dose of
loperamide or mebevarine may particularly be helpful for patients who have increased frequency of
bowel movements in the morning. Octreotide alters the conscious perception of rectal sensation and

may be useful in chronic pain syndromes84. Fedotozine acts on the peripheral opioid receptors
modulating sensory afferent pathways 85. A multicentre controlled trial has shown its effectiveness in
reducing abdominal pain intensity86,87. The effect of a Serotonin (5-HT3) receptor antagonist,
ondansetron has been assessed in a double blind placebo controlled trial in individuals with diarrhea
predominant lBS. There was improvement in stool consistency but not in frequency75,88. As there is
high prevalence of adverse reactions to food in diarrheic IBS, treatment with oral cromolyn sodium
may be of value in these patients76,89. Cisapride, a prokinetic drug, has Serotonin receptor agonist
(5HT3) and antagonist (5-HT4) actions. It influences interdigestive and postprandial small bowel motor
activity90, accelerates colonic transit and decreases the severity of constipation89.
Conclusion
In short, treatment of lBS has to be individualized according to the predominant symptom of the
patient. A combination of psychological support, dietary advice, change in the life style and appropriate
selection from the armament of drugs help in effectively combating symptoms and misery of the
patient. A positive physician patient interaction is associated with fewer return visits for lBS 92. lBS
patients with short duration and fewer psychological symptoms have a better prognosis than patients
with a long history of lBS and associated psychological stresses93.
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